TY - JOUR
T1 - Retrospective study of acute myelogenous leukemia in elderly patients
T2 - treatment and outcome of 83 consecutive patients
AU - Ino, T.
AU - Tsuzuki, M.
AU - Hasegawa, A.
AU - Miyazaki, H.
AU - Kojima, H.
AU - Maruyama, F.
AU - Okamoto, M.
AU - Matsui, T.
AU - Ezaki, K.
AU - Hirano, M.
N1 - Copyright:
This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PY - 2000/4
Y1 - 2000/4
N2 - We retrospectively analyzed treatments and outcomes for 83 acute myelogenous leukemia (AML) patients aged 60 years or more (median age 71) admitted to our hospital between August 1984 and January 1998. Complete remission was achieved in 36% of 78 patients who received anti-leukemic therapy, and median overall survival was 227 days. In addition to abnormal karyotypes involving chromosome 5 or 7, administration of less than 120 mg/m2/course of daunorubicin (DNR) during the initial treatment phase was an unfavorable prognostic factor for both CR and survival. Only 41% of all patients received 120 mg/m2/course of DNR or more, and had a significantly higher CR rate (56%) and longer survival, with a median of 389 days. It was suggested that intensive chemotherapy was effective for selected elderly AML patients who were relatively younger and had good performance status, although the number of such patients was limited in our study.
AB - We retrospectively analyzed treatments and outcomes for 83 acute myelogenous leukemia (AML) patients aged 60 years or more (median age 71) admitted to our hospital between August 1984 and January 1998. Complete remission was achieved in 36% of 78 patients who received anti-leukemic therapy, and median overall survival was 227 days. In addition to abnormal karyotypes involving chromosome 5 or 7, administration of less than 120 mg/m2/course of daunorubicin (DNR) during the initial treatment phase was an unfavorable prognostic factor for both CR and survival. Only 41% of all patients received 120 mg/m2/course of DNR or more, and had a significantly higher CR rate (56%) and longer survival, with a median of 389 days. It was suggested that intensive chemotherapy was effective for selected elderly AML patients who were relatively younger and had good performance status, although the number of such patients was limited in our study.
UR - http://www.scopus.com/inward/record.url?scp=0034168825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034168825&partnerID=8YFLogxK
M3 - Article
C2 - 10846460
AN - SCOPUS:0034168825
SN - 0485-1439
VL - 41
SP - 303
EP - 309
JO - [Rinshō ketsueki] The Japanese journal of clinical hematology
JF - [Rinshō ketsueki] The Japanese journal of clinical hematology
IS - 4
ER -